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Abstract
Background & Aims—Liver cancer has a very dismal prognosis due to lack of effective 
therapy. Here, we studied the therapeutic effects of hyper-interleukin15 (hyper-IL-15), which is 
composed of IL-15 and the sushi domain of the IL-15 receptor α chain, on metastatic and 
autochthonous liver cancers.
Methods—Liver metastatic tumour models were established by intraportally injecting syngeneic 
mice with murine CT26 colon carcinoma cells or B16-OVA melanoma cells. Primary 
hepatocellular carcinoma (HCC) was induced by diethylnitrosamine (DEN). A hydrodynamics-
based gene delivery method was used to achieve sustained hyper-IL-15 expression in the liver.
Results—Liver gene delivery of hyper-IL-15 robustly expanded CD8+ T and NK cells, leading 
to a long-term (more than 40 days) accumulation of CD8+ T cells in vivo, especially in the liver. 
Hyper-IL-15 treatment exerted remarkable therapeutic effects on well-established liver metastatic 
tumours and even on DEN-induced autochthonous HCC, and these effects were abolished by 
depletion of CD8+ T cells but not NK cells. Hyper-IL-15 triggered IL-12 and interferon-γ 
production and reduced the expression of co-inhibitory molecules on dendritic cells in the liver. 
Adoptive transfer of T cell receptor (TCR) transgenic OT-1 cells showed that hyper-IL-15 
preferentially expanded tumour-specific CD8+ T cells and promoted their interferon-γ synthesis 
and cytotoxicity.
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Conclusions—Liver delivery of hyper-IL-15 provides an effective therapy against well-
established metastatic and autochthonous liver cancers in mouse models by preferentially 
expanding tumour-specific CD8+ T cells and promoting their anti-tumour effects.
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Introduction
Hepatocellular carcinoma (HCC) has a very poor prognosis [1,2]. Traditional therapies for 
HCC such as surgery are limited by tumour size and intrahepatic metastases [3]. The only 
clinically approved chemotherapy drug for advanced HCC is sorafenib, which shows only 
modest efficacy, improving survival of patients by just 3 months [3,4]. Therefore, there is an 
urgent need to develop more effective therapeutic strategies for liver cancer. Accumulating 
evidence shows that immunotherapy might become a potential therapeutic option for 
patients with HCC [5]. Adoptive transfer of autologous T lymphocytes, stimulated by anti-
CD3 and IL-2, into patients with HCC significantly improved post-surgical recurrence-free 
survival [6]. Recently, Sangro et al. showed attractive evidence for the application of 
CTLA-4 targeted immunotherapy in patients with HCC [7].
Administration of cytokines to enhance immune responses has proven to be an effective 
immunotherapy for some cancers [8]. IL-2 has been used to treat metastatic melanoma 
patients [9,10]. IL-15, a cytokine that shares many features with IL-2, including the use of 
two receptor subunits (IL-2Rβ and IL-2Rγ) and similar intracellular signalling, also shows 
anti-tumour activity in mice [10]. IL-15 promotes proliferation and effector function of 
CD8+ T cells, natural killer (NK) cells and NKT cells [10]. More attractively, IL-15 shows 
no obvious adverse effects in vivo, such as T-cell activation–induced cell death or expansion 
of T regulatory cells, compared to IL-2 [10]. Trans-presentation of IL-15 by IL-15Rα on 
activated monocytes and dendritic cells to the IL-2R/IL-15Rβ and γ chain on effector T, B, 
and NK cells is thought to be the primary mechanism for IL-15 action [11,12]. Recent 
reports have shown that administration of preformed complexes of IL-15 with its soluble 
receptor IL-15Rα (amino acids 1–78) enhanced the bioavailability of IL-15 by about 50-fold 
and showed elevated tumour-eliminating effects in vivo [13–16]. This complex led to an 
extended half-life of IL-15 in vivo and robust proliferation of antigen-experienced CD44hi 
CD8+ T cells, NK cells and NKT cells [13–16]. Importantly, the soluble fusion protein of 
IL-15Rα (amino acids 1–78) and IL-15, linked by a flexible pep-tide, exhibited enhanced 
activity relative to non-covalently associated IL-15 and sIL-15Rα in vitro and in vivo 
[17,18].
Considerable efforts have been mounted towards testing the anti-tumour activity of the 
IL-15/IL-15Rα-Fc complex or fusion protein in several cancer models in mice 
[13,15,18,19]. However, its therapeutic benefit for HCC has not been clearly defined. The 
idea of targeting the IL-15 pathway to treat liver cancer is further supported by the finding 
that higher IL-15 protein levels in peritumoural liver tissues are significantly associated with 
better prognosis in patients with resected HCC [20]. Chang et al. recently reported the 
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therapeutic use of AAV8-delivered IL-15 superagon-ist (IL-15/IL-15RαS) in a mouse model 
of metastatic HCC [21]. However, this treatment was only shown to be effective when 
administered at very early time points (3 days after intrasplenic injection of tumour cells), 
limiting the translational relevance. The effects of a IL-15 superagonist on more established, 
clinically relevant tumours, such as autochthonous HCC models [22], remains unknown.
In this study, we used the hydrodynamics-based gene delivery method to express a fusion 
protein of soluble IL-15Rα, fused with IL-15 and human IgG1-Fc (designated as hyper-
IL-15 hereafter) in vivo to treat liver cancers. We report that ectopic hyper-IL-15 expression 
had significant therapeutic effects on both well-established metastatic and autochthonous 
liver cancers in mice, and these effects were primarily mediated by CD8+ T cells. 
Mechanistically, hyper-IL-15 could preferentially expand tumour-specific CD8+ T cells and 
enhance their cytotoxic activity. Our results have significant implications for the application 




Female C57BL/6 (B6) and BALB/c mice (aged 6–8 weeks) were obtained from Weitong 
Lihua (Beijing, China). OT-1/Thy1.1 mice were obtained by backcrossing B6 Thy1.1 and 
OT-1 mice purchased from Jackson Laboratory. All mice were maintained in a specific 
pathogen-free barrier facility at the Institute of Biophysics. All animal studies were 
approved by the Institutional Laboratory Animal Care and Use Committee.
Antibodies and reagents
The fluorescently-labelled anti-mouse NK1.1, CD3, DX5, CD4, CD8, B7-H1, FoxP3, 
CD25, CD11b, CD11c, CD90.1 (Thy1.1), and IFN-γ antibodies, brefeldin A solution and 
Cytofix/Cytoperm™ kit were purchased from eBioscience (San Diego, CA). Rabbit anti-
asialo GM1 (a-GM1) antiserum and control rabbit serum were purchased from Wako Pure 
Chemical (Tokyo, Japan). CD8+ T cell depletion antibody (α-CD8, clone TIB210), NK1.1+ 
cell depletion antibody (α-NK1.1, clone PK136) and rat anti-KLH mAb (rat IgG2a) were 
purified from ascites of nude mice. H-2Kb tetramer SIINFEKL-PE was purchased from 
Beckman Coulter.
Vector construction, recombinant protein preparation
Construction of the hIgG-Fc (Fc), mouse hyper-IL-15-Fc (hyper-IL-15), IL-15 and IL-15-Fc 
expression cassettes is shown in Supplementary Fig. 1A. The proteins were prepared by 
transient transfection of 293T cells and purified by protein G columns.
Hydrodynamic-based gene delivery
For each mouse, 10 μg DNA was diluted in 2.0 ml of PBS (0.1 ml/g body weight) and 
injected into the tail vein using a 27-gauge needle over 5 to 8 s. In vivo gene expression was 
confirmed by detecting the protein in the serum by ELISA.
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Metastatic or autochthonous liver cancer models
Metastatic liver tumours were established by injecting 1 × 105 CT26 or 3 × 105 B16-OVA 
tumour cells in 150 μl PBS solution into mice through the portal vein using a 32 G needle. 
To induce autochthonous liver cancers, 15-day-old male C57BL/6 mice were injected 
intraperitoneally (i.p.) with 25 mg/kg DEN (Sigma, St. Louis) dissolved in DMSO. Visible 
liver nodules were counted and nodule size was measured with calipers by measuring two 
perpendicular.
Flow cytometry
Splenocytes and intra-hepatic lymphocytes (IHLs) were prepared as described [23]. Cells 
were pre-incubated with anti-CD16/32 mAb and then stained with surface or intracellular 
markers. Flow cytometry was performed on FACSCalibur (BD Bioscience, San Jose, CA) 
and data were analysed with FlowJo software (TreeStar, Ashland, OR).
In vivo cytotoxicity assay
The in vivo cytotoxicity assay was performed as described in the Supplementary Materials 
and methods and as described previously [24].
Histology and immunohistochemistry
The paraffin embedded tissues were sliced (5 μm) and stained with haematoxy-lin-eosin. 
Frozen sections (5 μm) were stained with rat anti-CD8α (eBioscience, San Diego, CA) or rat 
IgG2a control antibody (eBioscience, San Diego, CA) and then developed with the Polink-1 
HRP detection system for rat primary antibodies (ZSGB-BIO, Beijing). The slides were 
scanned with a Leica SCN 400 (Leica Camera, Allendale, NJ) and images were analysed by 
using SlidePath Gateway (Leica Microsystems Inc.).
Statistics
Statistical analysis was performed using the two-tailed, unpaired Student’s t test (*p<0.05; 
**p<0.01; ***p<0.001; ns, non-significant) using GraphPad Prism 5 software (GraphPad 
Software, La Jolla, CA).
Results
Hyper-IL-15 robustly expands CD8+ T cells and NK cells in the liver
To evaluate the therapeutic effect of hyper-IL-15 on liver cancer, we used hydrodynamics-
based gene delivery, which achieves high expression of plasmid DNA by hepatocytes [25]. 
After hydrodynamic injection of the hyper-IL-15 plasmid, the level of hyper-IL-15 in the 
plasma reached a peak at day 1 and then decreased over time, reaching low levels after 
around 2 weeks (Supplementary Fig. 2A). At day 4 after hydrodynamic injection, the total 
number of intrahepatic lymphocytes (IHLs) increased up to 70-fold in hyper-IL-15 treated 
mice compared with the Fc-treated control group. The absolute numbers of CD8+ T cells 
and NK cells were 200-fold higher in the hyper-IL-15 group than that in the control group, 
while CD4+ T cells were just slightly increased in hyper-IL-15-treated mice. 
Correspondingly, the percentages of CD8+ T cells and NK cells were significantly 
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increased, and the percentages of CD4+ T cells were dramatically decreased after hyper-
IL-15 delivery (Fig. 1A). Similar results were obtained in the spleen (Supplementary Fig. 
3A). In contrast, expression of IL-15 alone only slightly increased the number of CD8+ T 
cells and NK cells in the liver (Supplementary Fig. 3B). Intravenous injection of 
recombinant hyper-IL-15 protein also significantly increased the number of CD8+ T cells 
and NK cells in liver (Supplementary Fig. 3C). Although hyper-IL-15 treatment induced 
robust accumulation of CD8+ T cells and NK cells in the liver, no obvious liver damage was 
observed in hyper-IL-15-treated mice compared to control mice as indicated by the alanine 
aminotransferase (ALT) level in the plasma (Supplementary Fig. 2B).
Next we determined the dynamics of CD8+ T cells and NK cells expanded by hyper-IL-15. 
As shown in Fig. 1B, the CD8+ T cell increase, induced by hyper-IL-15 treatment, persisted 
much longer than that of NK cells in the peripheral blood. At day 40 after the hydrodynamic 
injection, the percentage and number of CD8+ T cells were still 2-fold higher in the livers of 
hyper-IL-15-treated mice than in control mice (Fig. 1C). These results demonstrate that 
hyper-IL-15 markedly expanded CD8+ T cells and NK cells in vivo, leading to a long-term 
accumulation of CD8+ T cells in the liver.
Hyper-IL-15 exerts remarkable anti-tumour effects on liver metastatic tumours
To study the therapeutic effect of hyper-IL-15 on metastatic liver tumours, we intraportally 
injected CT26 colon carcinoma cells or B16-OVA melanoma cells into syngeneic mice. 
Disseminated metastatic tumours in the liver were palpable at day 10 and became extremely 
serious by day 15 (Supplementary Fig. 4A). We treated the tumour-bearing mice with hyper-
IL-15 or Fc control plasmids by hydrodynamic injection at day 10 and evaluated the 
therapeutic effect at day 18 after tumour inoculation. As shown in Fig. 2A and 
Supplementary Fig. 4B, most mice in the Fc control group showed serious disseminated 
tumours that had merged together, while only a few scattered tumour nodules were observed 
in livers of hyper-IL-15-treated mice. The liver weight varied between individual mice in the 
Fc control group, with livers weighing 1.5 and 2.8 times more on average than those of 
hyper-IL-15-treated mice in the CT26 and B16-OVA tumour models, respectively. Thus, 
hyper-IL-15 showed impressive therapeutic effect on well-established metastatic tumours in 
the liver.
CD8+ T cells mediate the therapeutic effect of hyper-IL-15
Similar to the results in tumour-free mice, hyper-IL-15 treatment dramatically increased 
both CD8+ T cells and NK cells in the livers of tumour bearing mice detected by flow 
cytometry and immunohistochemical staining (Supplementary Fig. 5). Next, we examined 
the contribution of each cell population to the suppression of metastatic liver tumours by 
depleting CD8+ T cells or NK cells respectively with antibodies during hyper-IL-15 
treatment. The specific depletion effects were verified by flow cytometry analysis of 
PBMCs (Supplementary Fig. 6). As shown in Fig. 2B, systemic depletion of CD8+ T cells 
completely abrogated the therapeutic effects of hyper-IL-15 on metastatic liver CT26 
carcinomas, whereas depletion of NK cells had minimal effect. Similar results were obtained 
in the B16-OVA tumour model (Fig. 2C). These results demonstrate that liver expression of 
hyper-IL-15 dramatically suppressed growth of liver metastatic tumours, and was mediated 
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by CD8+ T cells, while expansion of NK cells had negligible effects on the anti-tumour 
efficacy of hyper-IL-15.
Hyper-IL-15 enhances the cytotoxic function of tumour-specific CD8+ T cells
Tumour-specific T cells, which are the major effector cells against tumours, are usually 
rendered tolerant during tumour development [26]. Here, we examined the effects of hyper-
IL-15 on tumour-specific CD8+ T cell responses. B6 mice were adoptively transferred with 
naive thy1.1+ OT-1 T cells and then intraportally injected with B16-OVA melanoma cells. 
After 10 days, the mice with palpable metastatic tumours in the liver were treated by 
hydrodynamic injection of hyper-IL-15 or Fc control vector. Compared with the Fc vector, 
hyper-IL-15 treatment dramatically increased CD8+ T cells by 18.7 and 19.9 fold 
respectively and, to a greater extent, increased adoptively transferred OT-1 cells by 62.2 and 
82.4 fold in liver and spleen, respectively, in B16-OVA tumour-bearing mice (Fig. 3A). 
Correspondingly, the percentage of OT-1 cells in CD8+ T cells was 3.2 and 4.4 fold higher 
in the liver and spleen of hyper-IL-15-treated mice compared to Fc-treated control mice 
(Fig. 3A). This result suggests that hyper-IL-15 preferentially expanded tumour-specific 
CD8+ T cells.
To analyse the cytotoxicity of tumour-specific CD8+ T cells in vivo, the hyper-IL-15 or Fc-
treated tumour-bearing mice were intravenously injected with a 1:1 mixture of spleen cells, 
pulsed with either OVA-257 peptide (SIINFEKL) or control HBV-S208 peptide 
(ILSPFLPL), which was labelled with carboxyfluorescein succinimidyl ester (CFSE) in high 
or low concentrations respectively, to serve as target cells. Splenocytes were collected 6 h 
thereafter to analyse CFSE-labelled cells for cytotoxicity determination. As shown in Fig. 
3B, the effective elimination of OVA peptide-loaded cells was observed in hyper-IL-15 
treated mice but not in the control group. The mean specific lysis in the hyper-IL-15 treated 
group was 80%, significantly higher than the observed 4% in the Fc-treated group. Thus, 
hyper-IL-15 markedly promoted the cytotoxic activity of tumour-specific CD8+ T cells in 
vivo.
To further analyse the effect of hyper-IL-15 on the function of tumour-specific CD8+ T 
cells, we isolated OT-1 splenocytes from naive or tumour-bearing mice 4 days after hyper-
IL-15 treatment and treated them with OVA-257 peptide ex vivo. The IFN-γ producing OT-1 
T cells were detected by flow cytometry. As shown in Fig. 3C, thy1.1+ OT-1 T cells from 
tumour naive mice could be stimulated by OVA peptide to produce IFN-γ, and hyper-IL-15 
treatment markedly increased the IFN-γ producing OT-1 T cells in the spleen of naive mice. 
However, OT-1 cells from the Fc-treated tumour-bearing mice did not react to OVA peptide 
stimulation, and the percentage of IFN-γ+ cells in OT-1 splenocytes was only 5% in 
comparison with 25% in naive mice. This result indicated that tumour-specific CD8+ T cells 
were functionally deficient or tolerant in mice with metastatic liver tumours. Impressively, 
OT-1 T cells from hyper-IL-15-treated tumour-bearing mice responded well to OVA peptide 
stimulation, with 45% of spleen OT-1 cells producing IFN-γ, which was similar to the 47% 
of IFN-γ+ OT-1 T cells from hyper-IL-15-treated naive mice (Fig. 3C). Thus, tumour-
specific OT-1 cells in tumour-bearing mice were fully activated after hyper-IL-15 treatment.
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These results demonstrate that hyper-IL-15 treatment not only expanded the number of 
tumour-specific CD8+ T cells, but also greatly enhanced their anti-tumour activity in mice 
with liver metastatic tumours.
Hyper-IL-15 treatment triggers pro-inflammatory cytokine production and significantly 
increases the ratio of CD8+ T cells vs. Treg cells in the liver
We also tested whether hyper-IL-15 treatment triggered other pro-inflammatory cytokines 
important for tumour elimination. As shown in Fig. 3D, hyper-IL-15 induced robust IL-12 
and IFN-γ, but not IL-10, in the plasma of tumour bearing mice 4 days after treatment. In 
parallel with tumour growth, expression of the co-inhibitory molecule B7-H1 on dendritic 
cells (CD45+CD11b+CD11c+) was upregulated, and regulatory CD4+ T cells (Treg cells) 
accumulated in the liver (Supplementary Fig. 4C). Hyper-IL-15 treatment could 
downregulate the expression of B7-H1 on dendritic cells (Fig 3E). Although hyper-IL-15 
treatment expanded intrahepatic T cells in general, including CD4+ T cells, the percentage of 
Treg cells in the CD4+ T cell population and the overall number of Treg cells was not 
significantly increased in liver (Fig 3E). Correspondingly, the ratio of CD8+ T cells, which 
underwent strong expansion, vs. regulatory T cells, which did not, was dramatically 
increased by hyper-IL-15 treatment (Fig 3E). These data suggested that hyper-IL-15 
treatment activated anti-tumour immune pathways without inducing immune suppressive 
pathways in liver.
Hyper-IL-15 shows significant therapeutic effect on autochthonous hepatocellular 
carcinoma
We further studied the potential of hyper-IL-15 for clinical application by using the 
diethylnitrosamine (DEN)-induced autochthonous hepatocarcinogenesis model in which 
malignant cells mostly arise from normal indigenous hepatocytes and grow slowly in 
immunocompetent mice. Male mice were intraperitoneally injected with DEN 15 days after 
birth and HCC developed within 8 months. Starting at 8.5 months, the mice were given two 
rounds of hydrodynamic injections of hyper-IL-15 or Fc plasmids with an interval of two 
weeks. Two months after the second treatment, all mice underwent hepatectomy. Mice 
treated with Fc exhibited massive multi-nodular HCCs, while mice treated with hyper-IL-15 
had only a few small, sporadic tumour nodules (Fig. 4A). The mean largest tumour volume 
and the total volume of all tumours per mouse were respectively about 80-fold and 100-fold 
smaller in hyper-IL-15-treated mice than that in Fc-treated mice (Fig. 4B). Depletion of 
CD8+ T cells by antibody administration during treatment partially diminished the 
therapeutic effects of hyper-IL-15 (Fig. 4A–C). Tumour nodules in the liver were confirmed 
by histochemical staining (Fig. 4C).
Taken together, our studies demonstrate that liver delivery of hyper-IL-15 has significant 
therapeutic effects on both metastatic and autochthonous liver cancers.
Discussion
We demonstrated here that liver gene delivery of hyper-IL-15 not only dramatically 
inhibited the growth of well-established liver metastatic tumours, but also exerted a 
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remarkable therapeutic effect on primary hepatocellular carcinoma. The anti-tumour effect 
of hyper-IL-15 was mediated mainly by CD8+ T cells, but not by NK cells. We found that 
hyper-IL-15 could enormously expand CD8+ T cells in vivo, cause long-term accumulation 
of CD8+ T cells in the liver, and markedly promote functions of tumour-specific CD8+ T 
cells.
Although hyper-IL-15 tremendously expanded both CD8+ T cells and NK cells in vivo, the 
results of lymphocyte deletion showed that the anti-tumour effects of hyper-IL-15 were 
dependent on CD8+ T cells rather than NK cells. This was consistent with the more durable 
accumulation of CD8+ T cells relative to NK cells in the liver. Chang et al. recently reported 
that the therapeutic effect of AAV-delivered hyper-IL-15 on metastatic murine liver cancer 
was mediated by NK cells rather than T cells [21]. In their study, mice were treated with 
AAV8/IL-15-IL-15RαS three days after tumour inoculation. At this time point, the tumours 
might not be well-established in the liver. In addition, the AAV itself may have triggered 
specific pathways to induce innate and adaptive immune responses against both viruses and 
tumours [27], complicating the interpretation of these experiments with respect to the effects 
of IL-15/IL-15Rα. Here, we show the impressive therapeutic effect of hyper-IL-15 to well-
established tumours in the liver 10 days after transplantation. Most importantly, we 
demonstrate that hyper-IL-15 dramatically inhibited the growth of well-developed DEN-
induced primary HCC. To our knowledge, this is the first immunotherapy, which shows 
significant therapeutic effects on DEN-induced autochthonous HCC.
Liver is recognized as a tolerogenic organ [28]. T cells that recognize antigens in the liver 
are usually exposed to inhibitory ligands, including B7-H1, and to immunosuppressive 
cytokines, including TGF-β1 and IL-10, which are expressed by liver antigen presenting 
cells such as dendritic cells, Kupffer cells, liver sinusoidal endothelial cells (LSECs) and 
even hepatocytes [29,30]. Thus, the indigenous tolerogenic hepatic environment potentially 
hinders HCC-directed immunotherapy. It was reported that the IL-15/IL-15Rα complex or 
fusion protein promoted the destruction of established pancreatic tumours by reviving 
tumour-resident CD8+ T cells and eliminated well-established myeloma by stimulating 
CD8+ T cells to produce IFN-γ [15,19]. In our liver metastatic B16-OVA melanoma model, 
tumour-specific OT-1 cells failed to respond to OVA peptide stimulation ex vivo, suggesting 
a tolerant state. Hyper-IL-15 therapy preferentially expanded tumour-specific OT-1 cells, 
and rescued their cytokine production ability and cytotoxic activity. We also found that 
hyper-IL-15 treatment triggered the production of IFN-γ and IL-12, but not IL-10, in tumour 
bearing mice. The expression of the co-inhibitory molecule B7-H1 on dendritic cells in the 
liver was also lower in the hyper-IL-15 treated mice compared to controls. These results 
demonstrated that, in the tolerogenic liver environment, hyper-IL-15 therapy could rescue 
tolerant tumour-specific CD8+ T cells to eliminate tumours.
In conclusion, our study showed that liver delivery of hyper-IL-15 had a remarkable 
therapeutic effect on liver metastatic tumours and even on primary HCCs by enhancing 
tumour-specific CD8+ T cell responses. Our encouraging results warrant future exploration 
of the use of hyper-IL-15 for treating metastatic and spontaneous liver cancers in humans.
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Fig. 1. Liver gene delivery of hyper-IL-15 expands both CD8+ T cells and NK cells in vivo
C57BL/6 mice were hydrodynamically injected with 10 μg of hyper-IL-15 or Fc plasmid at 
day 0. (A) Intrahepatic lymphocytes (IHLs) were isolated for flow cytometry analysis at day 
4. Numbers of total IHLs (left), cell numbers (middle) and percentages (right) of CD8+ T 
cells (CD3+CD8+), CD4+ T cells (CD3+CD4+), NK cells (CD3−NK1.1+) in IHLs are shown. 
Three independent experiments with similar results were performed. (B) Percentages of 
CD8+ T cells (left) and NK cells (right) in PBMCs at indicated time points. (C) Cell 
numbers (left) and percentage (right) of CD8+ T cells in IHLs in each group at day 40. 
Graphs represent the mean ± SEM of 3–5 mice each group in A, B and C.
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Fig. 2. Therapeutic effect of hyper-IL-15 on liver metastatic tumours
BALB/c or C57BL/6 mice were intraportally injected with CT26 tumour cells or B16-OVA 
melanoma cells and then hydrodynamically injected with hyper-IL-15 or Fc plasmids at day 
10. (A) Representative photographs and liver weight with disseminated metastatic CT26 
tumours (upper panels) and B16-OVA tumours (bottom panels) at day 18 are shown. Three 
independent experiments with similar results were performed. (B–C) Some tumour-bearing 
mice were injected i.p with 200 μg CD8+ T cells (a-CD8) or NK cells (a-GM1or a-NK1.1) 
depletion antibodies 1 day before and 4 days after hydrodynamical injection of the hyper-
IL-15 plasmid. Representative photographs and liver weight with disseminated metastatic 
CT26 tumours (B) and B16-OVA tumours (C) at day 18 are shown. Two independent 
experiments with similar results were performed. Each dot represents one individual mouse 
and graphs represent the mean of 5–10 mice each group.
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Fig. 3. Hyper-IL-15 preferentially expands tumour-specific CD8+ T cells and enhances their 
cytotoxic function
Thy1.2+ C57BL/6 mice were adoptively transferred with purified thy1.1+ OT-1 T cells one 
day before they were intraportally injected with B16-OVA cells, followed by hydrodynamic 
injection with hyper-IL-15 or Fc plasmids 10 days after tumour inoculation. (A) The 
absolute number and percentage of total CD8+ T cells, number of thy1.1+ OT-1 T cells and 
percentage of OT-1 cells in total CD8+ T cells in the spleen and IHLs are shown. (B) Mice 
were i.v. injected with a 1:1 mixture of CFSE-labelled spleen cells, pulsed with OVA-257 
peptide (right peak) or control HBV-S208 peptide (left peak) 4 days after hyper-IL-15 
treatment. After 6 h, splenocytes were isolated and CFSE profiles were analysed. The 
numbers above the peaks indicate percentages of OVA-257 peptide-pulsed cells among the 
total CFSE-labelled target cells. Specific lysis of peptide pulsed target cells was calculated. 
Graphs represent the mean ± SEM of 3–4 mice each group in A and B. (C) Four days after 
hyper-IL-15 or Fc treatment, splenocytes were harvested and stimulated ex vivo with 1 
ng/ml OVA-257 peptide for 2 days and IFN-γ+ -producing cells were detected by 
intracellular staining. Representative plots of IFN-γ+ OT-1 cell cells are shown (left). 
Percentages of IFN-γ+ OT-1 cell were statistically analysed (right). Each dot represents one 
individual mouse and graphs represent the mean of 3 mice each group. (D–E) C57BL/6 mice 
were intraportally injected with B16-OVA melanoma cells and then hydrodynamically 
injected with hyper-IL-15 or Fc plasmids at day 10. At day 14, cytokines IL-12, IFN-γ and 
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IL-10 in the serum were detected by Luminex assay (D). B7-H1 expression on dendritic 
cells, percentage and number of Treg cells and CD8+ T cells vs. Treg cells in the liver at day 
14 are shown (E). Two independent experiments with similar results were performed.
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Fig. 4. Therapeutic effect of hyper-IL-15 on DEN-induced autochthonous hepatocellular 
carcinoma
Male C57BL/6 mice were i.p. injected with DEN 15 days after birth, and hydrodynamically 
injected with hyper-IL-15 or control Fc plasmids at 8.5 and 9 months. Some hyper-IL-15-
treated mice were i.p. injected with 200 μg of anti-CD8 antibody 1 day before and 4 days 
after each hydrody-namic injection. At 11 moths, all mice underwent hepatectomy. (A) 
Representative photograph of livers with HCCs. (B) Size of the largest tumour (left) and 
total tumour volume (right) in each liver were measured and statistically analysed. Each dot 
represents one individual mouse and graphs represent the mean of 4–10 mice each group. 
(C) Representative H&E staining of liver tissue sections before or after treatment. Black 
dash lines indicate border of the tumour nodules.
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